Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis. - Wikidata - awgldk - TriplyDB

Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.

Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.

http://www.wikidata.org/entity/Q37778738

about

Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.Extremely elevated IL-18 levels may help distinguish systemic-onset juvenile idiopathic arthritis from other febrile diseases.

P2860

Q34646212-BEA19856-9A89-4C4C-83C2-7C82754E7199 Q40322015-CE922FA6-883A-476D-A564-4BE6F8B790DF

P2860

Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.

http://www.wikidata.org/entity/Q37778738

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tocilizumab: The evidence for ...... juvenile idiopathic arthritis.

@en

Tocilizumab: The evidence for ...... juvenile idiopathic arthritis.

@nl

type

label

Tocilizumab: The evidence for ...... juvenile idiopathic arthritis.

@en

Tocilizumab: The evidence for ...... juvenile idiopathic arthritis.

@nl

prefLabel

Tocilizumab: The evidence for ...... juvenile idiopathic arthritis.

@en

Tocilizumab: The evidence for ...... juvenile idiopathic arthritis.

@nl

P1433

Q37778738-7E924970-205B-4D18-BFC6-CBE7B4362723

P1476

Q37778738-AFA057AB-C429-4727-B521-7C434611E2B4

P2093

Q37778738-6A7D98C7-9763-4D7F-9E02-AA2E8EC94B51

P2860

Q37778738-0B0BBA26-9A11-4526-8D07-5E9E90C3AC2A

Q37778738-0CF95898-2826-406A-9790-BD3A75412076

Q37778738-255D5861-4D24-4E33-9499-5214CA09A834

Q37778738-2B6F85F0-4E91-4D11-8380-4ACAD0FEEF26

Q37778738-2CCEFF34-F84F-4763-9F7A-003ABC3C4C84

Q37778738-2DA577BD-7D70-4FEE-8C42-9BF86BBAE6D8

Q37778738-31EA5B51-C21C-489F-B979-AAA4198ACC58

Q37778738-32253C09-47CB-48A4-A1E4-2B85297B0F2E

Q37778738-3B581843-0BFC-4C12-BD05-EC99A2160F72

Q37778738-44531375-3FDE-4E47-BAB9-695175444431

P304

Q37778738-989A4A17-B001-403C-8607-864FDA1876C8

P31

Q37778738-91319C68-8D6D-4DD3-9BE3-6536A461F89F

P356

Q37778738-44D48E7E-0B0B-4B27-A599-18C6200333F7

P407

Q37778738-8DCAE040-B8C6-4B2C-9F30-860AE57D5CD1

P478

Q37778738-69B5A171-105E-45AB-8282-32A7E78C6F40

P577

Q37778738-84B73424-643D-485F-ABC5-C41AA331B434

P698

Q37778738-7E653540-634D-4608-8720-555207B9C241

P921

Q37778738-AFEA9E50-FEDB-4581-8FDC-1B2D29C6311F

P932

Q37778738-9C58F8C1-7636-4F79-910E-8269807791EF

P356

P1433

P1476

Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis

@en

P2093

Troels Herlin

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolong

International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001

IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.

Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

Anti-B cell and anti-cytokine therapy for the treatment of post-transplant lymphoproliferative disorder: past, present, and future.

P304

181-189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CE.S5992

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20694074

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis

P932

2899792

http://www.w3.org/2001/XMLSchema#string